Previous Article | Next Article 
Journal of Virology, September 2007, p. 10029-10036, Vol. 81, No. 18
0022-538X/07/$08.00+0 doi:10.1128/JVI.02241-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Bortezomib Induces Apoptosis of Epstein-Barr Virus (EBV)-Transformed B Cells and Prolongs Survival of Mice Inoculated with EBV-Transformed B Cells
Ping Zou,
,
Junichi Kawada,
Lesley Pesnicak, and
Jeffrey I. Cohen*
Medical Virology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892
Received 12 October 2006/
Accepted 5 July 2007
Bortezomib, an inhibitor of the 26S proteasome, is currently approved for treatment of multiple myeloma and is being studied for therapy of non-Hodgkin's lymphoma. We found that Epstein-Barr virus (EBV)-positive B cells with type III latency were more susceptible to killing by bortezomib than those with type I latency. Bortezomib induced apoptosis of EBV lymphoblastoid cell lines (LCLs) by inducing cleavage of caspases 8 and 9; apoptosis was inhibited by pretreatment with a pan-caspase inhibitor. Bortezomib reduced the levels of the p50 and p65 components of the canonical NF-
B pathway and reduced the level of p52 in the noncanonical NF-
B pathway, which is induced by EBV LMP1. Bortezomib inhibited expression of cIAP-1, cIAP-2, and XIAP, which are regulated by NF-
B and function as inhibitors of apoptosis. Bortezomib did not inhibit expression of several other antiapoptotic proteins, including Bcl-2 and Bcl-XL. Finally, bortezomib significantly prolonged the survival of severe combined immunodeficiency mice inoculated with LCLs. These findings suggest that bortezomib may represent a novel strategy for the treatment of certain EBV-associated lymphomas.
* Corresponding author. Mailing address: Laboratory of Clinical Infectious Diseases, National Institutes of Health, 10 Center Drive, Building 10, Room 11N234, Bethesda, MD 20892. Phone: (301) 496-5265. Fax: (301) 496-7383. E-mail:
jcohen{at}niaid.nih.gov
Published ahead of print on 11 July 2007.
P.Z. and J.K. contributed equally to this paper.
Present address: Department of Microbiology, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.
Journal of Virology, September 2007, p. 10029-10036, Vol. 81, No. 18
0022-538X/07/$08.00+0 doi:10.1128/JVI.02241-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Kawada, J., Zou, P., Mazitschek, R., Bradner, J. E., Cohen, J. I.
(2009). Tubacin Kills Epstein-Barr Virus (EBV)-Burkitt Lymphoma Cells by Inducing Reactive Oxygen Species and EBV Lymphoblastoid Cells by Inducing Apoptosis. J. Biol. Chem.
284: 17102-17109
[Abstract]
[Full Text]
-
Krug, L. T., Collins, C. M., Gargano, L. M., Speck, S. H.
(2009). NF-{kappa}B p50 Plays Distinct Roles in the Establishment and Control of Murine Gammaherpesvirus 68 Latency. J. Virol.
83: 4732-4748
[Abstract]
[Full Text]
-
Satheshkumar, P. S., Anton, L. C., Sanz, P., Moss, B.
(2009). Inhibition of the Ubiquitin-Proteasome System Prevents Vaccinia Virus DNA Replication and Expression of Intermediate and Late Genes. J. Virol.
83: 2469-2479
[Abstract]
[Full Text]
-
Liu, J., Enomoto, S., Lancto, C. A., Abrahamsen, M. S., Rutherford, M. S.
(2008). Inhibition of Apoptosis in Cryptosporidium parvum-Infected Intestinal Epithelial Cells Is Dependent on Survivin. Infect. Immun.
76: 3784-3792
[Abstract]
[Full Text]
-
Le Clorennec, C., Ouk, T.-S., Youlyouz-Marfak, I., Panteix, S., Martin, C.-C., Rastelli, J., Adriaenssens, E., Zimber-Strobl, U., Coll, J., Feuillard, J., Jayat-Vignoles, C.
(2008). Molecular Basis of Cytotoxicity of Epstein-Barr Virus (EBV) Latent Membrane Protein 1 (LMP1) in EBV Latency III B Cells: LMP1 Induces Type II Ligand-Independent Autoactivation of CD95/Fas with Caspase 8-Mediated Apoptosis. J. Virol.
82: 6721-6733
[Abstract]
[Full Text]
-
Wilson, S. J., Tsao, E. H., Webb, B. L. J., Ye, H., Dalton-Griffin, L., Tsantoulas, C., Gale, C. V., Du, M.-Q., Whitehouse, A., Kellam, P.
(2007). X Box Binding Protein XBP-1s Transactivates the Kaposi's Sarcoma-Associated Herpesvirus (KSHV) ORF50 Promoter, Linking Plasma Cell Differentiation to KSHV Reactivation from Latency. J. Virol.
81: 13578-13586
[Abstract]
[Full Text]